Journal
STEM CELL REVIEWS AND REPORTS
Volume 14, Issue 3, Pages 337-345Publisher
SPRINGER
DOI: 10.1007/s12015-018-9809-x
Keywords
Mesenchymal stem cells; Metabolic syndrome; Diabetes; Aging; Senescence; Regenerative medicine; Oxidative stress; Autophagy
Funding
- National Science Centre (NCN) [2016/21/B/NZ7/01111, 2015/18/E/NZ9/00607]
- Wroclaw Centre of Biotechnology, the Leading National Research Centre (KNOW) programme
Ask authors/readers for more resources
Mesenchymal stem cells (MSC) have become a promising tool for therapeutic intervention. Their unique features, including self-renewal, multipotency and immunomodulatory properties draw the worldwide attention of researchers and physicians with respect to their application in disease treatment. However, the environment (so-called niche) from which MSCs are isolated may determine their usefulness. Many studies indicated the involvement of MSCs in ageing and disease. In this review, we have focused on how type 2 diabetes (T2D) and metabolic syndrome (MS) affect MSC properties, and thus limit their therapeutic potential. Herein, we mainly focus on apoptosis, autophagy and mitochondria deterioration processes that indirectly affect MSC fate. Based on the data presented, special attention should be paid when considering autologous MSC therapy in T2D or MS treatments, as their therapeutic potential may be restricted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available